JP2022137047A5 - - Google Patents

Download PDF

Info

Publication number
JP2022137047A5
JP2022137047A5 JP2022096439A JP2022096439A JP2022137047A5 JP 2022137047 A5 JP2022137047 A5 JP 2022137047A5 JP 2022096439 A JP2022096439 A JP 2022096439A JP 2022096439 A JP2022096439 A JP 2022096439A JP 2022137047 A5 JP2022137047 A5 JP 2022137047A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
alkyl
acceptable salt
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022096439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022137047A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/067855 external-priority patent/WO2018119208A1/en
Application filed filed Critical
Publication of JP2022137047A publication Critical patent/JP2022137047A/ja
Publication of JP2022137047A5 publication Critical patent/JP2022137047A5/ja
Pending legal-status Critical Current

Links

JP2022096439A 2016-12-22 2022-06-15 ヒストンメチルトランスフェラーゼ阻害剤 Pending JP2022137047A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662438121P 2016-12-22 2016-12-22
US62/438,121 2016-12-22
PCT/US2017/067855 WO2018119208A1 (en) 2016-12-22 2017-12-21 Histone methyltransferase inhibitors
JP2019531160A JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019531160A Division JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2022137047A JP2022137047A (ja) 2022-09-21
JP2022137047A5 true JP2022137047A5 (https=) 2023-03-20

Family

ID=60972497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531160A Expired - Fee Related JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤
JP2022096439A Pending JP2022137047A (ja) 2016-12-22 2022-06-15 ヒストンメチルトランスフェラーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019531160A Expired - Fee Related JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤

Country Status (7)

Country Link
US (2) US10829452B2 (https=)
EP (2) EP3558971B1 (https=)
JP (2) JP7091336B2 (https=)
AR (1) AR110443A1 (https=)
ES (2) ES2981507T3 (https=)
TW (1) TW201829386A (https=)
WO (1) WO2018119208A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7091336B2 (ja) * 2016-12-22 2022-06-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
AU2018353139A1 (en) * 2017-10-18 2020-06-04 Epizyme, Inc. Methods of using EHMT2 inhibitors in immunotherapies
JP2021500326A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 血液障害の予防又は処置にehmt2阻害剤を使用する方法
DE112019001222T5 (de) 2018-03-09 2020-11-26 Schlumberger Technology B.V. Integrierte Bohrlochkonstruktionssystem-Betriebsvorgänge
CN111196817B (zh) * 2018-11-19 2021-06-11 四川大学华西医院 作为brpf1抑制剂的三环化合物
EP3929185A4 (en) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
CN111620818B (zh) * 2019-02-28 2023-09-29 暨南大学 8,9-二甲氧基啡啶类化合物及其应用
CN116710431A (zh) * 2020-11-19 2023-09-05 泰洛治疗公司 小分子化合物和组合物
WO2022115377A1 (en) * 2020-11-24 2022-06-02 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
WO2022162471A1 (en) 2021-01-27 2022-08-04 Vandria Sa Urolithin derivatives and methods of use thereof
CN113004294B (zh) * 2021-03-08 2023-01-17 温州大学新材料与产业技术研究院 一种四氢呋喃并1,4-二氢喹啉类化合物及其制备方法和应用
CN114573569B (zh) * 2022-03-30 2023-07-04 邦恩泰(山东)生物医药科技集团股份有限公司 一种异喹啉类化合物的制备方法
CN117903150A (zh) * 2024-01-11 2024-04-19 中国科学技术大学 一种烯基取代的多环氮杂环的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HK1054039B (zh) 2000-03-15 2010-04-16 萨诺费-阿文蒂斯德国有限公司 取代的β-咔啉
CA2510375A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
AU2006212765B2 (en) * 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
BRPI0719123A2 (pt) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
JP2010519267A (ja) 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
AU2009314760B2 (en) * 2008-11-11 2011-11-10 Je Il Pharmaceutical Co.,Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
WO2011133795A2 (en) 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
CA2803697A1 (en) 2010-06-25 2011-12-29 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
KR101827444B1 (ko) 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
WO2015110263A1 (en) 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
US9284272B2 (en) 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
CN106536509B (zh) * 2014-06-16 2020-06-09 基础应用医学研究基金会 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物
AU2016356884A1 (en) * 2015-11-16 2018-06-21 Fundación Para La Investigación Médica Aplicada Novel compounds as inhibitors of dna methyltransferases
JP7091336B2 (ja) * 2016-12-22 2022-06-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤

Similar Documents

Publication Publication Date Title
JP2022137047A5 (https=)
CA3081983A1 (en) Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
US9643977B2 (en) Necroptosis inhibitors and methods of use therefor
KR102543559B1 (ko) 설폰아미드화합물 또는 이의 염
JP2019031560A5 (https=)
JP2020504716A5 (https=)
CA2950072C (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
JP2021502403A5 (https=)
JP2024511996A5 (https=)
JP2004531490A5 (https=)
JP2017510642A5 (https=)
CA2668997A1 (en) 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2012500805A5 (https=)
JP2018522032A5 (https=)
JP2014514317A5 (https=)
JP2007519659A5 (https=)
JP2019524883A5 (https=)
JP2019513743A (ja) インドールアミン 2,3−ジオキシゲナーゼ阻害剤、その製造方法及び応用
CN118119618A (zh) 一种杂芳环类化合物及其应用
JP2019519587A5 (https=)
JP2009534406A5 (https=)
JP2017510643A5 (https=)
JP2019532974A5 (https=)
JP2020505356A5 (https=)
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用